In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...
A retrospective review of the pharmacy computer database was performed to identify hemodialysis patients with central venous catheters who received alteplase or urokinase for presumed catheter ...
Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices
Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors PURPOSE: To determine whether cryopreserved solutions of ...
In the wake of recently announced shortages in the availability of Cathflo® Activase®, commonly used to restore patency in occluded catheters1, ICU Medical, Inc. ICUI said that its Neutron catheter ...
Nuvelo is forging ahead with phase 3 trials on its blood-clot buster enzyme alfimeprase, with results expected early next year. The recombinant enzyme attracted the attention of Bayer Healthcare, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results